Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chronic Cough: 50 Patient Proof of Concept Study Completed in 10 Months in UK.
https://www.businesswire.com/news/home/20220629005372/en/Axalbion-Announces-Positive-Findings-from-Phase-2-Clinical-Study-in-Chronic-Cough-with-AX-8-a-Novel-TRPM8-Agonist
https://clinicaltrials.gov/ct2/show/NCT04866563
Jacky Smith (Principle Investigator) is on the Advisory Board of both Algernon Pharmaceuticals and Bellus Health, and likely other companies. She's a hired gun for Chronic Cough. It would appear that Algernon is the only company that struggles enormously to get to data results. It has everything to do with location and cheap tricks. Will management ever change their wicked ways?
https://algernonpharmaceuticals.com/medical-and-scientific-advisory-board/
https://bellushealth.com/about-us/our-company/#chronic-cough-cab
"“We look forward to testing AX-8 in this proof-of-concept study, as there are currently no approved treatments for chronic cough. By activating TRPM8, our goal is to decrease the upper airway sensitivity in chronic cough patients, and reduce coughing and throat irritation,” said principal investigator Jacky Smith, MD, professor of respiratory medicine at the University of Manchester, UK."
https://WWW.BUSINESSWIRE.COM/news/home/20211020005271/en/Axalbion-Announces-First-Patients-Treated-in-Phase-2-Clinical-Trial-in-Chronic-Cough-with-AX-8-a-Novel-TRPM8-Agonist
https://axalbion.com/
M$
See @ ceo.ca
ceo.ca/agn?63ef3efc7944
M$
A bad choice of hard to prove endpoints. No Stelar results/data recorded during the crazy scrambles at the foreign hospitals. Everyone was getting 'Remdeathisnear' to confound some data results. *
AGN should Never had a 40 mg arm.!.
Investors and CSO/CEO were aiming for a home run when baserunners were what was needed then. A simple treatment, Not "the Cure" BS...IMO...
Some good data still and the IL-6 stuff too.
"Feedback from the FDA" and a pass at the DSMB, but they never applied for the Phase 3. Fair point.
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/53/algernon-pharmaceuticals-receives-green-light-from-dsmb-to
Continued supporting data from the CC/IPF study for the use of Ifenprodil in chronic lung diseases seems probable.
IMO, do the $2M to keep rolling. ASAP. Prepare the next stepss ..GLTA...
*{Gilead (Wuhan V.I.-Bat Soup) Rem} bought up All the hospital beds to use for Rem CTs that eventually also showed no real results...IMO...
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/35/algernon-pharmaceuticals-announces-topline-data-from-its
<>
The Company’s decision was based on several factors including the overall findings of the Phase 2b COVID-19 study final data set, the global rate of vaccinations to date, other COVID-19 drug treatment programs under development, and the projected trial size, costs and timelines needed to successfully complete a Phase 3 trial. Feedback recently received from the U.S. Food and Drug Administration regarding the Company’s end of Phase 2 meeting request was also informative.
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/25/algernon-pharmaceuticals-announces-it-will-not-advance
Pricing of Public Offering of Units
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Pricing-of-Public-Offering-of-Units?id=362616
STINK TO HIGH HEAVEN
IMO, only a fool would continue sitting on their hands and knees watching their chances at a decent ROI slip away because of ongoing shenanigans @ virtual office HQ. What further shenanigans do you need to endure before taking action, another 100 to 1 reverse split in 2023?
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com
I will reiterate once again, your chances of getting any significant ROI will come down to what decision management makes with the proceeds from the Public Offering. If they decide to barrel ahead with Phase 1 studies you are toast for at least the next 5 years. If they do the right and obvious thing, they will take the money and run a Gold Standard Phase 2 study for Chronic Cough in the USA ASAP.
Chronic Cough is the fast track to a billion dollar market cap. Moreau cannot point to any other faster avenue if one even exists with Cancer or Stroke or CKD. They're all long shots far off into the distant future. Chronic Cough is here and now. Strike while the iron is hot (momentum and market interest) and finally give Bellus Health a run for the money versus blowing hot are on webcast claiming Bellus Health is a pure comparison to Algernon Pharmaceuticals.
Prove it in Words and Deeds Christopher Moreau (CEO).
Good Luck To All In All Your Endeavors In Life,
M$
On the issue of the COVID-19 study being FDA approved to move to a Phase 3 clinical trial... PROVE IT.
You're saying it's so because Christopher Moreau said so...LMAO. As I've already stated, that study was not powered for statistical significance. In Moron Moreau's OWN WORDS, he told the market the study would have needed overwhelming data to move to Phase 3. If you believe Algernon had the means/money to run a real Gold Standard - 2000 patient study to try to get to statistical significance, I have a bridge to sell you.
Had they gotten statistical significance from a Gold Standard Phase 2 clinical trial, Algernon would likely have gotten all kinds of financial help to move forward in their efforts. You cannot get around the fact of having been duped by double talk coming from management.
The two COVID-19 studies in South Korea and Romania were both trash @ss studies that had no chance from the outset. As witnessed by South Korea study never getting off the ground (Schleprock). The data coming from the IPF/Chronic Cough study will be recycled into another Phase 2 study maybe, maybe not. Who knows?
On April Fools Day 2021 this news dropped:
www.cantechletter.com/2021/04/take-a-pass-on-algernon-pharmaceuticals-says-mackie/#
Ifenprodil was approved to move to a Phase 3 COVID related trial. The COVID pandemic was wanning and vaccines from BP were being pushed. So not pursued.
Ifenprodil had specific positive effects, Data from the CC/IPF study may be related. BFD, IMO.
AGN/NASH is in Australia, so was the study.
I have seen a DMT trial for determining minimum dose levels for psychedelic results already done in the UK. We are all waiting for some news from there. BFD, IMO...
These two seem to be the main focus NOW...
...GLTA...
.
At long last, through all the smoke and fire, pain and suffering, blood and guts, I've clearly and convincingly found my exit out of Dante's Inferno (Algernon Pharmaceuticals Inc.). It's been documented here in plain and EZ to understand English. There is no doubt the masses of AGNPF shareholders entered through the doors of purgatory and found themselves fighting like hell. Whatever level of the journey shareholders find themselves in, I hope one day they too will find their peace.
I Have
Have @ It
M$
The Inferno PostScript
Christopher Moreau has controlled the direction of Algernon Pharmaceuticals since Q1 2018. The company purchased a repurposed drugs strategy from Nash Pharmaceuticals in Q4 2018. Of the four leading compounds purchased by Algernon, only one of those drugs have been advanced into a so-called Phase 2 study. The business strategy that you were sold underhandedly led you to believe they could run expeditious Phase 2 studies that would immediately move to Phase 3 given a successful data readout. However, that is not what you were truly sold. The truth is Algernon runs cheap studies in countries outside of North America that are not designed to move beyond Phase 2. Their business model actually requires at minimum twice as many years at Phase 2 than many other biotech companies. IMO, shareholders continue to endure a long drawn out and underhanded scam since becoming Algernon Pharmaceuticals in 2018. In summary, Algernon Pharmaceuticals has taken nearly 4 years to run a study on just one of its originally intended disease targets. It won't be until Q4 2022 or Q1 2023 before you receive a Final Data Readout for IPF/Chronic Cough (an ultra low budget 20 patient study). Algernon has not pursued their repurposed NASH or IBD drugs since their purchase from Nash Pharmaceuticals in 2018. Each being 30% of the overall cost to acquire such drugs. Algernon has only recently decided to pursue CKD with NP-251 (Repirinast), a drug tested preclinical back in 2019.CKD was also 30% of the overall cost to acquire such drugs, which required a 2 to 1 reverse split and subsequent doubling of shares thereafter (dilution on steroids). Sound familiar? Go figure. NP-251 was a Phase 2 entry level drug that is now a Phase 1 entry level drug.
Adding insult to injury, your management team has thrown out the speedy Phase 2 scam and reverted backwards to Phase 1 studies for all drugs in the pipeline. The company has moved backwards. Any claims to start from preclinical advancing directly to Phase 2 clinical trials is now a false and misleading statement. However, don't let that stop Algernon from still claiming it with pipeline graphics and other such ill literature. By the time Algernon Pharmaceuticals ever gets to its very 1st Randomized Double Blind Placebo Controlled Study Powered For Statistical Significance (THE GOLD STANDARD), it will be the year 2025 if you're lucky with Schleprock as your CEO. That's a 7 Year bad luck timeline to get real world data that will determine if your 1st leading compound will make it to a Phase 3 clinical trial. Christopher Moreau peddled the story of you having a 65% chance of success at Phase 2 to move to Phase 3 with both the COVID-19 study and pending IPF/Chronic Cough results. Moreau said that knowing neither of those studies were powered for statistical significance. Meaning, neither of those studied had/have a chance of advancing to Phase 3. You have been royally duped by management. It's incredible the company has not been sued by now. See the list of companies at the following link who ran clinical trials during Algernon's disastrous IPF/Chronic study in Australia.
pact.lungfoundation.com.au/find-a-trial/
You can see Algernon sticking out like a sore thumb when it comes to the Gold Standard for clinical trials. Algernon is a low rank company that peddles cheap penny stock shares and warrants to support insider lifestyles. No more. No less. No foreseeable changes in the future.
Of Note: Christopher Moreau told shareholders in at least one of those scripted webcasts where he spoke to people at other biotech companies and told them he could run Phase 2 studies on the cheap. None of those other biotech companies believed a word that he said. It’s most likely because Christopher Moreau was not talking about running Gold Standard studies like they were. Christopher Moreau was talking in another language. He was talking about running straight up BS studies that merely continue to waste shareholders' valuable time and money before ever running a straight forward clinical trial at Phase 2. You are screwed for at least the next 5 years if Algernon does not pivot ASAP to directly running a Gold Standard Phase 2 study in North America for Chronic Cough. That’s your only reasonable chance at the bogus “65% chance of success” spouted out of the mouth’s of Christopher Moreau (CEO) and Dr. Mark Williams (CSO) .
Schleprock @ The Helm of Algernon Pharmaceuticals Inc.
PostScript II
The Days Of Naivete 5+ Years Ago @ Breathtec Biomedical Inc.
/investorshub.advfn.com/boards/read_msg.aspx?message_id=129824673&txt2find=world
Simple math. You are apparently holding your shares expecting a significant PPS raise to sell in to, provided by the possible success of at least one of the three (4) paths that AGN is attempting. Tough projects with possible good rewards.
Speculating like all the rest of us shareholders. Everyone does DD. All know the Good and Bad possibilities and have made the Risk to Reward assessment as defined by their personal opinions. You're holding. So am I.
...GLTA...
If simple math and management’s expressed plans for the pipeline timeline moving forward does not reasonably explain how expecting a 10,000% Return On Investment (a 100 bagger) is wishful thinking at best - nothing will. I’ve laid out a reasonable expectation of dilution for the foreseeable future as management chases after super long-shot cancer studies and brain surgery (stroke) with a psychedelic drug. A pertinent and smart question to ask is why aren't you asking management what the hell are they doing about running a speedy Phase 2 clinical trial in North America for Chronic Cough ASAP - 1 year from start to finish(?). Sitting back thinking Moreau has it all figured out shall be a detriment to your cause. It’s obvious from past practice that their timelines are not advantageous to your time and money. They own 2% of the current shares and get paid no matter how the stock performs. When/how do you go about holding them accountable? By expecting someone else to do the heavy lifting or voicing your own concerns? It’s called activism. It’s a myth to think you can’t make a difference. The most logical path to maximizing the market cap with the least amount of shenanigans by management (ohhh there will be plenty more if you let them) is throwing all effort/money at Chronic Cough. Simply consider the fact they believed it was OK to spin the company on a dime and throw nearly all of Algernon’s capital at chasing COVID-19 down a black hole. They knew the odds were incredibly stacked against an underpowered study to reach statistical significance to move to a Phase 3 clinical trial. Moreau finally admitted as much in the lead up to the Final Data Report for COVID-19.Moreau beat the drum of success right up until the Final data readout was imminent. Moreau’s ultimate excuse thereafter was “What If We Had Not…” ran a study for COVID-19?
The guy truly believes he can do no wrong…no wrong that he will ever be held accountable for.
What if management had not run an unpowered study for COVID-19?
The Answer Is Simple:
The company would not have been driven straight over a cliff into the Abyss.
The company would have retained the cash for the Phase 1’s in the pipeline now.
It’s the primary reason for a 100 to 1 reverse split and capital raise at All-time lows.
https://www.scribbr.com/statistics/statistical-power/ -
Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Issuance-of-Patent-for-Ifenprodil-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis?id=362124
VANCOUVER, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has been issued a patent from the Canadian Intellectual Property Office (“CIPO”), No. 3101853, for the treatment of interstitial lung disease with NP-120 (“Ifenprodil”), entitled “Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis.”
The invention claims treating interstitial lung disease, including idiopathic pulmonary fibrosis (“IPF”), with Ifenprodil. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company also has active patent applications for Ifenprodil for the same compositions and methods in the U.S., Europe, China and Japan.
Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications covering method of use for new disease indications, as well as dosing and formulation. In addition, the Company has filed new composition of matter patents for novel salt forms for some of its lead compounds.
“We are very pleased to be granted this patent by the CIPO,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “This is an important milestone for the Company as we continue to strengthen our global IP position.”
About Ifenprodil
Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils and certain types of cancer cells.
The Company is conducting a proof-of-concept Phase 2 human trial to determine the safety and efficacy of Ifenprodil in patients with IPF and its associated cough and recently announced it had reached database lock.
Topline data from this study is expected in July 2022.
Just so we’re all clear here. The pattern of news release events prior to imminent data is playing out in the same way it did to the run up to COVID-19 Topline data. At that time management put out news releases stating the following:
January 19, 2021
ABSOLUTELY!!!
Certainly a good sign.
Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended
VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE)
Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, announces that patients from multiple sites participating in its Phase 2 proof of concept study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and chronic cough, being conducted in Australia and New Zealand, have requested ongoing supply of Ifenprodil for their personal use beyond the study’s treatment period. The company is helping the clinical sites obtain additional supply of the drug through the Australian Government’s Special Access Scheme; a mechanism which allows patients to access unapproved therapeutic goods.
As previously stated, the Company is projecting that topline data from the Phase 2 study will be available in July 2022.
The Company is advising that it is not making any express or implied claims that Ifenprodil has the ability to cure or treat IPF or chronic cough at this time.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed intellectual property rights globally for Ifenprodil for the treatment of respiratory diseases.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
The UK has not approved Algernon's Phase 1 DMT study
In this one instance I agree with tcm55. There is nothing in writing that suggests a DMT study has been given the go ahead to start in the UK. To my knowledge the application process is a 60 to 90 day window for approval. Algernon filed an application back in January 2022 (more than 150 days ago) and have not updated the public on it's status since. Instead, you are being dangled around the supposed start of DMT in Q3 2022. A timeline that's continued to get pushed back 1 2 3 quarters at a time. The stupidity never ends with how management communicates with shareholders. It's always some level of Smoke & Mirrors involved in everything coming out of the CEO's virtual office. Be it in writing or verbal. Any money raised by the clown team in the latest bomb fire sale of shares and warrants should go to getting results from a Phase 2 Chronic Cough clinical trial conducted in North America ASAP - results from start to finish within 12 months. We know it's possible because Bellus Health did it for it's shareholders. Aggressive timeline versus weak and fickle Christopher Moreau's decisions. Without it, you will continue suffering massive dilution and slow rolled data studies in other far away countries where he will attempt to lay the blame for a slow train to any data readouts. Moreau loves pointing the finger at everyone and everything else for his transparent ignorance at the helm of a publicly traded company. Christopher Moreau continues to make deals with the devil year after year with your money burning in his hands and burning a hole in your pocket.
Have @ it
M$
All That Jazz & Math
9 Million USD is a paltry number to raise capital on Wall Street. If you've paid any attention you realize Wall Street simply ain't buying what Algernon is peddling nowadays. Hence, "management" is now hat in hand at CSE penny world.
Your logic suggests people scrounging for pennies in-between their couch cushions is the best group of would-be investors equipped to raise 9M. So 9M is EZ money for the masses of little money trading on CSE versus magic money from the 24 carat yellow brick road - Land Of Oz?
Yeah...ok.
The Market Cap has dropped because the story continues to fall apart. Have you followed and understood the F-1 filings at SEC? The offering continues to drop like a rock. Thus, bonehead management will increase dilution by multiples which now includes matching warrants.
You keep talking about approvals this and that. Approvals for what? To my knowledge they are not waiting for anything but money. Must the FDA approve of tiny trials outside of the USA? Trials that likely will never be run in North America at any phase of the process? Algernon's business model is about running dirt cheap studies in countries with slow rolled enrollment for maximum dilution opportunities, including second world countries where fires break out at sites where all your data is stored.
In regards to the ongoing drumbeat about "averaging down" and expecting losses and all that jazz…how about telling that story-line to this poster here:
A 'measly $9M' is twice the MC. I dont know if there is another LS% or other person/group that CAN make those kinds of speculative investments. We're waiting impatiently for confirmations and acceptance from the UKMHRA or FDA. Duh.
The COVID chase results were 'not stellar' enough to do a Phase 3 directed at the flagging COVID epidemic. NONE of the other COVID treatments were either. BP can $pread their true lies. Remdesivir, PFE-MRNA (C-19 specific) vaccines.?. AGN does not have a Dr Fakee to twist spins, only a fairly honest CSO describing 'trends' in a herd of BP$ B$.
Unconfident and opinionated claims of incompetence? GLWT in the mirror. Future or past, crystal balls or Hind sighting others. Talk to the mirror again, IMHFO....
Trading advice may be heeded. Mitigating some losses due to 'not stellar' COVID results seemed obvious as AGN sought complementary paths that may use the Data gleaned from existing work and new paths with possibilities. NO Guarantees from ANY company EVER that I have seen..
Buy-Hold-Sell.
...GLTA...
You make some great points.
That’s exactly what I’m here for. Another BLO type run.
GLTA
You’ll Get No Rainbows & Unicorns Here
Wall Street has rejected Algernon’s latest business strategy requiring a measly $9M in capital to launch.
If any of the clinical trials in the pipeline spelled fast turnaround investment dollars as you suggest, Moreau would not be right back at Pimp Smack Mackie bending over backwards to make another deal with the devil.
Two things glaringly (like warning lights) come to mind when I think of all the happy talk about Algernon since they torched the FAIMS deal:
"Everybody Wants In At Phase 2" - Christopher Moreau
"We Have A 65% Chance Of Success Because Safety Is Not An Issue" - Christopher Moreau (CEO) & Dr. Mark Williams (CSO).
Moreau & Con-pany will tell you ANYTHING (AS SEEN LIVE ON WEBCAST) to continue selling cheap shares to support their lifestyles.
Dr. Mark Williams even bailed out of Algernon to launch his own biotech company. Only to return not as the Chief Science Officer, but as a Director now void of being the point man for burning the midnight oil to cook the books with repurposed drugs theories.
Let Moreau tell it, Doc Williams adds a "secret sauce" to how he comes up with his repurposed drugs theories. Apparently Doc Williams has enough secret sauce to spread around for his personal cook book as well at Marvel Biosciences.
Chase the lies upon lies all you want. I'm only here now for the long drawn out data readout of 20 people with zero chance of statistical significance.
Let's watch how Andre Uddin spins this next Topline report since he's now on the payroll of Algernon. Is he going to trash the report and further crash the stock like he did the last time?
There's so much interwoven shenanigans to the Algernon story it would be impossible for a newbie to catch up to this ongoing soap opera starring Drama Queen Christopher Moreau.
Yet, you have the same common shareholder bending over backwards to justify all the wrong they see right before their eyes. Pure denial is a new phenomenon sweeping the globe like the plague. A common sense set of facts can no longer be had for the common good.
As I previously stated, Wall Street rejected the repurposed drugs plan hat in hand. They are experts at what they do. Do we have any experts here? No, we have bag holders who have been overwhelmed by sheer incompetency, legalized corruption (thank you CSE and OTC penny world), lies and more lies, continuous unfortunate surprises, reverse splits and dilution that is burying us all alive.
Yeah, keep giving me more of all of that at Phase 1 now.
Furthermore, when I speak of a 1 Trick Pony in my last post, I am specifically talking about the DMT angle for Stroke. If you look around for the true contenders (at least that’s what the overall market believes) in the psychedelic space, they all have multiple approaches to psychedelic treatments.
The ATAI’s - the Compass Pathways - the Cybin’s - the Mindmeds - even GHRS has 2 angles for its DMT drug. Algernon has an incredibly unlikely path to success with a Hail Mary for brain surgery. It makes for a good story but unfortunately one that Wall Street ain’t buying.
Shell says look at the ETF’s. Ok…and? Algernon has already participated in the Horizons ETF:
https://www.horizonsetfs.com/horizons/media/pdfs/pressreleases/2021/20210326_PSYKRebalance.pdf
The next horizon for Algernon is another steep cliff that will leave you flat in no time flat.
The “reorganization” of Algernon Pharmaceuticals was merely a whitewash to bury past incompetence and lies and presplt common shareholders. They assume you don't understand math and will simply go along with having gotten buried under a ton of newly issued shares and warrants. You're not understanding that every share sold moving forward represents 100 shares you held before the reverse split. The orchestrated capital raise on the CSE are shares being sold for 3 CENTS WITH A WARRANT. 3 CENTS. You need $30 on average to break even with pre split shares. Do you truly believe the cast of characters at Algernon is capable of turning Algernon into a multi-billion dollar company in your lifetime? By the time they’re done running their tiny Phase 1’s and Phase 2’s (not powered for stat sig) in slow rolled countries like Australia they will have run the outstanding shares north of 100 million and some shareholders will likely be dead and gone. Algernon is merely a stock selling scheme to support Moreau and friends lifestyles. Moreau thinks he’s a real catch. See him in his plunging necklines devoid of a tie all the time. Surely it goes well with being bent over the railing of someone's yacht in the Cayman Islands and elsewhere.
To Hell Is Where The Lot Of Them Are Headed!
^ That’s One Thing I’d Bet The Farm On Moving Forward >
Have @ it
M$
Postscript
tcm55
So, approvals from the UK MHRA for Stroke research with micro dosed DMT wont attract serious interest.?. A real clinical application seems supported and we can assume there was some work needed.
An adjunct use of Ifenprodil with chemo for SCLC and cancer tumors may also be 'chased'. AGN licensed the IP.
One trick pony? Speculative investment and always has been, IMO.
The endpoints for the CC/IPF study will at least enable something CC. Maybe in Australia as AGN/NASH have THAT door as a solid backstay.
Most of us have been here through a lot chasing Breath and COVID. We know the past. There were obvious chances and risks.
I am speculating on the possible positive future.
These are ALL possibly big deals, IMO. A sustainable pipeline?
The current cards could be played quick as Shell implies some might. (imo). Long ago I posted to push the BTH run with small buys ( at least) to enable a BLO type run.
With some Positive Results and thoughtful actions AGN may move quick AND sustainably. .. (insert Sly + Family Stone @ Woodstock).
...GLTA...
...
You're talking all penny world stuff. Which is polar opposite of where the company claimed it was headed >>> NASDAQ. You're even throwing Kulwant Malhi (Cannabix's King Clown) into the equation as the supposed guy for financing, flipping and directing Doc Williams (the midnight reader). I mean that's all the old hits from 2018 you're expecting to be the case moving forward (but actually ass backwards). Who the hell wants to go back down that road? What's certain is I won't be someone here to continue ranting about any of those losers. As far as hanging your hat on the psych angle look around. Thus far the top contenders have shaved in excess of 50% off their Market Cap in the last month or so. If Wall Street is devaluing the psych sector, who thinks Algernon has a chance with it's pie in the sky one trick pony for strokes? It's the most extreme angle of any biotech out there chasing psych treatments. It makes for a good story (as long as Moreau isn't the one telling it) but not dollars and cents/sense. As I've said umpteen thousand times well before the split and long trail of Moreau's Drama Queen antics is the Chronic Cough angle is the only thing in the pipeline that has any chance at shareholders recouping loses. Wall Street has rejected all that BS Moreau brought to the table. Hence, back to the pennyland Abyss with an offering that doesn't even have a dollar amount attached to it. Anyone think it odd how the stock dropped a US dollar the following day and another 20% thereafter? They are orchestrating another massive dilution scheme where USA shareholders are locked out. The CADS are at it again. Go to CEO.CA and there's an insider who goes by the name sheepandpigs or whatever. Within his ranting posts he revealed Algernon was onto a "deal" that was not related to NASDAQ. My best guess is they had this planned all along. Why would you go to Wall Street and explicitly tell would be investors they could buy units where the warrants would never trade? Then you turn around and open the floodgates for warrants to trade on the CSE? They are running a massive underhanded dilution scheme and knew this latest news dump would punish the stock to the point of issuing even more shares than last filed with the SEC. F*** Moreau and the entire lot of them.
Burn In Hell
Thanks for the dialog. It beats trying to blame me for all the BS happening with the stock price. If one can't see how they are destroying any value of Algernon one needs their head examined by a board certified physician.
M$
“yeah what else to the story have I missed? I'd love to read others original thoughts.”
I could let you have @ this Angle of Thought
https://mailchi.mp/psychedelicfinance/june17-10135980?e=e795a0a94d
That Link above is “Psychedelic Finance” and list all Psychedelic stocks and there now (2) ETF’s on Psychedelic and coming soon is another I heard
Question is, the Dr that Kal had for NASH Pharma still @ work??
Nasdaq Stocks and Psychedelic ETF’s would be probably a Winner for pushing share price
As for Nasdaq — My Thought — Algernon Needs way more Cash to be there and going elsewhere to Raise the Cash needed for Nasdaq — JMO — Cash being Raised will only be enough to do a few of what their chasing
Bottom line on me — They said they were Approved Nasdaq @ $4.11 USA dollar and Stock was sitting $3
(25% uptick was a good Buy if one bought)
Watch out for the Shorts after the run like that
JMO — A run and a fake Short after a Big 50% or 100% run will be a Buy — Kal’s got the Cash threw others to Push this much Higher when ready — JMO
Here’s one I like and those in the Heat Wave - Hopefully you can feel the Chill - Happy Father’s Day Coming Soon
Following the math and common sense regarding pending clinical trials tells a story of doom and gloom on it's own accord. Going from a $5 offering to a $4 offering now likely a $3 offering with matching warrants is not positive by any stretch of the imagination. The math says you are losing your ass while stuck in the mud waiting for any movement on clinical trials or receiving a data readout in advance of raising more money. That too says they have no confidence in the long awaited IPF/CC data readout moving the needle upward. Otherwise why maximize dilution beforehand? The only website out there still trying to blow rainbows and unicorns out to the masses is ceo.ca. It's there you'll find mostly biopub members, fam and friends, bloggers wanting to pump for a quick flip. They have recently calmed down the rhetoric there as they too can see the rainbows and unicorns story falling apart. The NASDAQ uplist appears to remain in peril. It would appear trying to raise money in the USA was a bust. How's that sit with thinking an uplist will have the stock takeoff? Algernon is setting itself up to simply continue trading and fire sale raising capital in pennyland as it did before the crazy ass reverse split of 100 to 1. Again, simple math says a return of investment is slipping further and further away. Phase 1 studies will only increase the dilution. They will be back at the public begging for more money by this time next year. The Chronic Cough angle was their best chance at keeping the company from falling into the pit of hell and they royally blew it. Another Phase 2 study for Chronic Cough isn't even on the calendar to start again and it too would require massive dilution because the current capital raise doesn't account for such expenses. Simple simple simple math and common sense. I've read another's beliefs about where we are in the process the many times it's been posted here. It doesn't address the actual issues happening before our eyes. It's generalizations about some process believed yet to happen for whatever reasons. IMO, it's very confusing to say the least. Doom & Gloom...yeah what else to the story have I missed? I'd love to read others original thoughts.
“Always tell the truth. That way you don’t have to remember what you said” – Mark Twain
“The truth is heavy, therefore few care to carry it” – Unknown
Have @ It
M$
P.S. Once this latest Drama Queen circus act orchestrated by Christopher Moreau (who else?) blows through town, expect the stock to trade around $1 USD.
P.S.S. The good news for those who want to read posts filled with rainbows and unicorns is you'll get the last of my ass once the Top line Data is finally released. I'm no longer waiting for an uplist to Nasdaq having assumed it would potentially be a positive catalyst. It's a wrap on that as well now that we see (with our own eyes) the company has shamelessly reverted back to their sleazy tactics in pennyland. That's Christopher Moreau's way of concentrating on the fundamentals.
Nasdag/US F1 on 5-9 was for 45 days, ending 6-24?
CSE only for this F1?
Different requirements, registration and costs?
Until AGN gets something from UK MHRA about the Stroke initiative or from FDA for CC or oncology it's hard work and they need funds to pursue this all.?.
It seems that re-writing parts of the applications and/or specifics about the Trials are still in work.
Oncology and Stroke are tough areas. IPF/CC may be first. I had hope for quick UK Trial support and strong interest in Australia to continue the IPF/CC work. I hope applications to cancer foundation were made.
I'm not selling at these tree shakes at this point, stubborn and holding to see all the cards. < .003% of OS = -20+%?.........
...GLTA...
You get their email yesterday of a Placement which is not to be able to Trade USA and if bought it’s labeled “Restricted Share count”
SLIMEBALL NEWS DUMP AFTER-HOURS
It's Christopher Moreau and former Miraculins leadership running the company. What else would you expect at this point?
Testimony from a poster at Yahoo
Call it taboo. Call it voodoo. Neither is what I do. I simply tell my truth. I'm no long-er searching for an exit. The answer is now crystal clear in my mind's eye.
The Exit: NASDAQ Uplist and Topline Data Readout. Whichever is the latter shall become my infinitely final days posting here. Whether or not I and/or assembled team continue following this stock's journey and other biotechs in a different format remains a work in progress.
Stay tuned Algernauts,
M$
Outro For Algernon's Inferno:
…are you saying taboo to anyone thinking about getting in lol
It's been hashed and re-hashished (smoked) a quintillion times now regarding the FACT Breathtec Biomedical (now Algernon) & Cannabix collaborated on the EGG ZAK same device technology. Same tech, same lab(s), same pot of money used to push the tech forward. What you see at Cannabix has Algernon's DNA within it. So what there was proclaimed competition with Breathtec Biomedical. There remains competition with Cannabix as well. Very serious competition. It hasn't stopped Cannabix from pumping the hell out of a narrative about testing this-that-other for 8 years and counting. Bottom line is shareholders of Algernon got duped when Christopher Moreau came in with a wrecking ball and did the opposite of what he claimed verbally and in writing. Shareholders knew it was a wrap with the FAIMS technology well before Moreau officially scrapped the FAIMS device. How did shareholders know? By someone's Due Diligence on this message board (can't recall who) in finding out Dr. Richard Yost (brainchild) had jumped ship and went to work for Owlstone Medical - a so-called competitor. Neither Christopher Moreau nor Dr. Yost felt the need to inform shareholders of Yost's departure. Yost just sailed off into the sunset across the Atlantic without a word of gratitude to shareholders. F*** YOST & University of Florida & Cannabix Technologies Inc. If you read GVX post regarding Cannabix it eludes to the fact simply having a device to PUMP a story can sustain a company for years on end. However, Moreau's track record of storytelling remains dismal at best. He even ran out of running the mouth runway at Miraculins with his failed device(s) leading to bankruptcy. Yeah, all that's old is always new at Algernon Pharmaceuticals Inc. Including Dr. Williams (brainchild) having once bailed out of Algernon Pharmaceuticals Inc.
One point that should be fully understood regarding Algernon's position on the FAIMS technology: The road to success was not as difficult as it remains for Cannabix. Algernon's stated goal for the FAIMS tech was simply having a portable device where other scientists would use the device to explore/detect whatever they wanted to chase down beyond controlled substances. Cannabix has the same device that will do the same thing. They simply have used vague language in their presentations to make it appear less obvious they ripped off shareholders at Algernon. I'm of the firm belief it was all part of a cooked up deal involving the reverse takeover of Breathtec Biomedical by Nash Pharmaceuticals whose #1 shareholder was of course Kulwant Malhi. There hasn't been a single thing at Algernon since the Breathtec days where King Cobra hasn't found a way to ROYALLY screw over shareholders at every turn of events. Which includes Moreau and Doc Williams shamelessly going to work for King Cobra at failed First Responders Technologies. Malhi retained power over the CEO of Algernon long enough to flip millions upon millions of shares of AGN/PF on behalf of another company and himself. It's immoral if not illegal and shareholders suffer to this day for the bullshit Moreau does on behalf of himself and others with power over him. Moreau is a puppet. 4+ years of Moreau's leadership and where does the company stand other than at the edge of another cliff?
OAN: Yeah shell. I don't know why there's no filed communications at CSE regarding NASDAQ. All I know is CSE is a trash ass rock bottom stock exchange. That's obvious considering how the "conflicts of interest" clauses filed by companies listed on the CSE somehow doesn't cross over into the criminal arena.
In regards to the long awaited IPF/CC data readout, I'm of the belief it is thoroughly baked into the rotten cake. Just like the failed COVID-19 study was explained at the very last minute by Moreau...it will take an overwhelming amount of positive data to move the needle. The IPF/CC study was not powered for stat sig. Algernon will need to tee up another Phase 2 study before having a chance at Phase 3. Another long drawn out study in Australia is Algernon's current plan. Surely not a speedy trial in the USA like Bellus Health conducted from start to data readout within 1 year. Can you imagine the type of fire sale dilution that will occur between now and then with three or four other Phase 1 studies needing cash if any move forward? Moreau will have the outstanding share count back to 100 million in no time flat like Usain Bolt. All the while smiling and telling shareholders about wanting to change their lives in a significant way. Break even on pre-split shares will likely require Algernon to have a Market Cap in the billions of dollars. Short of a miracle that's the plan I see unfolding here. Algernon's umpteen million previous claims of entering the clinical trial phase at Phase 2 has been completely blown out of the water. You think Moreau would land another CEO job somewhere else in pennyland? Perhaps, but it's no longer necessary. Performance be damned due to weak shareholders. Moreau has structured a long-term income and retirement plan for himself @ Algernon Pharmaceuticals Inc.
It's A Lifestyle!!!
Yours truly,
M$
algernonpharma.com
algernauts.com
Yeah baby! Algernon is the best performing stock on my watchlist today!
Long and strong… Algernon all the way!
;)
I hope they surprise us in July with some incredibly successful chronic cough trial results. To me, it would be hilarious and amazing at the same time.
Hoping this stock eventually gives me the nice windfall BLOZF gave me years ago. BLOZF did it without a successful product, so I believe these guys can make it happen with some pipe-dream drugs in their pipeline. Good luck to all!
According to the latest F-1/A Registration Statement filed on 2022-05-09 with US SEC:
"We have applied to have our Common Shares listed on the Nasdaq Capital Market under the symbol "AGNP" and recently received approval to list our Common Shares on Nasdaq Capital Market."
Yes, hard to find. I Hope for Positive news on Stroke, IPF/CC Data and Clinical Trials and Oncology for SCLC and Pancreatic/tumors. Certainly ALL need the Best efforts from our company teams to make a successful IPO.
In this company review of actions and challenges, I found this Bth 'device' reference? A reason for the NASH deal? Ending UF licensing.
"In regards to its medical device, the Company has certain direct competition from Menssana Research Inc., which is based in New Jersey, U.S. and Owlstone Nanotech Inc., which is based in the United Kingdom.
These companies have the financial ability to compete directly with the Company"
Agn IP now at Blo as some say? Cant find that. Any residual value?
...GLTA...
It’s Dated April 27, 2022 also but is also the same one listed on CSE site and was Filed 04/27/2022 there
Maybe $AGNP is coming soon is why the late Filing on the OTC site — Have you noticed that the Nasdaq Listing is kinda hid from those using CSE only site? At least I have a hard time finding anything about trying for a Nasdaq listing
https://webfiles.thecse.com/AlgernonFeb2822MDA.pdf?MAKhYuiJrGBk8E.AiftdxmG.7z1MBhuO
https://www.otcmarkets.com/otcapi/company/financial-report/337180/content
From what I can tell, there isn't a new MDA filing since April 2022. Also, your MDA link is incorrect.
The burn rate from the quarter ending in February 2022 versus cash on hand points to the company being F L A T______B R O K E.
Peace,
M$
Condensed Interim Consolidated Financial Statements
https://www.otcmarkets.com/otcapi/company/financial-report/337179/content
Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Database-Lock-in-Phase-2-Study-of-IPF-and-Chronic-Cough?id=360894
The so-called CEO is bent over a barrel (probably lovin' it) as shareholders fingers (digits) continue getting cut off (draining/diluting blood) to raise capital for a cash strapped company on the brink of bankruptcy. Moreau's past immoral acts have finally caught up with him at the worst time in the worst way for shareholders. It's obvious that his words and deeds have yet to carry the day in the eyes of would be newbie investors. It's a silly ass eight million dollar capital raise (in the grand scheme of things) and he's struggling to meet the mark/moment. Everything he touches becomes a long drawn out struggle. How anyone believes Christopher J. Moreau is a real CEO needs their head examined. I wouldn't put that guy in charge of a lemonade stand much less running a public company. My best guess is if long-winded Algernon Pharmaceuticals survives it will be shorted to no end. Sub $1 days are on the horizon. Hold onto your ass. The next cliff will be much steeper than the last.
https://algernonpharma.com/
M$
Test your knowledge of psychedelic drugs... From Charles River Labs Finland, Eureka blog... Hmmm...GLTA...
https://www.criver.com/eureka
Correction: After the latest fire sale @ Algernon, Christopher Moreau will have effectively taken the company from less than 50 million shares fully diluted to more than 750 Million outstanding shares and north of 1 Billion shares fully diluted since his tenure. That's when you factor in both reverse splits of 2 to 1 and 100 to 1.
Full Stop
Having given the latest F-1/A another look, the Outstanding Shares including the giveaways will increase the outstanding to north of 5 Million Outstanding Shares not including the warrants. If the company survives through all the basement level Phase 1 studies in the pipeline, another massive dilution scheme will take place yet again to move any of them to Phase 2. From there, the question becomes whether or not any of those studies will be powered for stat sig or just another study to determine if they want to move to a real Phase 2 study powered for stat sig. The entire business model is set up for collosal and catastrophic dilution. Moreau will dilute the company back to 100 Million plus shares in no time flat. The pre reverse split shares will literally be worthless. As it would take a Billions upon Billions of dollars market cap to get close to break even. None of their plans are on your side and their timelines are set for them to retire at ripe old ages while draining the public of pennies with pathetic stories. These people have put on a master class of how penny world execs operate in the real world lowlife bowels of the stock market. I've yet to be proven wrong and the numbers don't lie.
Christopher Moreau's goal is to make a life changing difference for shareholders. Anybody remember that tripe spewing out of his mouth in one of those webcast stories?
Newsflash: Moreau wasn't really talking to you. He was talking to the people he loves cherishes and worships. Insiders and anyone else he enjoys getting bent over the rails of their yacht parked along the coastline anywhere in the world. A remote office location for the insiders...yeah I get. It's a lifestyle.
M$
Outstanding: 1,674,868 on June 7, 2022
Monthly 5th Report
https://webfiles.thecse.com/5._Algernon_-_CSE_Form_7_-_May.pdf?e4OhHq9hZhO3NgVaBr5QfJ90Mxd5EzNx
Trouble Trouble and more Trouble
The latest dilution plan has now gone from - "This prospectus relates to an underwritten public offering of 1,931,922 units (the "Units") of Algernon Pharmaceuticals Inc., each Unit consisting of one Class A Common Share (the "Common Shares") and one warrant (the "Warrants"), based on an assumed offering price per Unit of US$4.348"
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322011852/formf1a.htm
To - "This prospectus relates to an underwritten public offering of 2,133,333 units (the "Units") of Algernon Pharmaceuticals Inc., each Unit consisting of one Class A Common Share (the "Common Shares") and one warrant (the "Warrants"), based on an assumed offering price per Unit of US$4.125."
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322014238/formf1a.htm
Trouble selling a 4 cents pre reverse split (100 to 1) stock story to family friends Cayman Islands ghost ship investors, etc etc.
It Remains Amateur Hour (+Days, Weeks, Months, Years) @ Algernon Pharmaceuticals Inc.
After the latest fire sale @ Algernon, Christopher Moreau will have effectively taken the company from less than 50 million shares fully diluted to more than 750 Million outstanding shares and north of 1 Million shares fully diluted since his tenure. That's when you factor in both reverse splits of 2 to 1 and 100 to 1.
The dilution moving forward will be at a clip that someone who can't even calculate 2 + 2 will understand. That's if the company ever moves forward >>>
M$
Memorial Day: Remembering Our Fallen Soldiers
Open Question: Go to Page 3 of Algernon Pharmaceuticals - Financial Statements for quarter ended February 28, 2022:
https://webfiles.thecse.com/AlgernonFEB2822FS.pdf?AqxYNIv1.sQXRJQuDMoQZ7yyBewc9eZL
Do you see the type of money being spent on Marketing & Shareholder Communications?
Now look here:
https://www.godaddy.com/domainsearch/find?checkAvail=1&domainToCheck=algernonpharma.com
What I'm saying is the company should have secured this web address from the very beginning. It's the most logical web address for ease of use - less characters is better than more characters. Management should wise up. Someone at yahoo even got livid over it stating there should be legal actions involved. Yeah, that makes a lot of sense. Pay lawyers instead of securing something that can better enhance their overall exposure. Website/email etc etc etc... I'm no expert but I know "algernonpharma.com" looks better than algernonpharmaceuticals.com and the name itself AlgernonPharma versus Algernon Pharmaceuticals. If you go to Algernon's twitter page it says Algernon Pharmaceuticals@AlgernonPharma. It would seem logical that someone thought AlgernonPharma makes sense for Twitter - but not their corporate web address? They don't have to take heed but spending money on a relentless slew of Fly-By-Night web videos is hardly a comparison to rock solid domain name(s).
What the experts say:
https://www.networksolutions.com/blog/establish/domains/why-secure-more-than-one-domain-for-your-business-
Think Clearly:
https://expat-solution-coaching.com/wp-content/uploads/2019/01/its-just-business.jpg
Hav @ It
M$
Outro
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |